Pregabalin Capsule
Product Images NDC 0904-6991

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 0904-6991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 00)

Label for Major Pharmaceuticals Pregabalin Capsules, 300 mg strength, oral capsules packaged in a unit dose of 30 capsules. The label includes dispensing instructions, Rx only designation, and storage conditions. The labeler is Major Pharmaceuticals, located in Livonia, MI, USA.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 01)

Packaging label for Major Pharmaceuticals PREGABALIN CAPSULES 225 mg, oral capsules, unit dose. The label states 'Rx only' with a quantity of 30 capsules. It includes PHARMACIST: DISPENSE WITH MEDICATION GUIDE and storage instructions to keep between 15° to 30°C. The label also lists the NDC 0904-7004-04 and manufacturing details for Major Pharmaceuticals and distributors.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 02)

PREGABALIN 200 mg capsules label from Major Pharmaceuticals for oral use. The unit dose package contains 30 capsules. The label includes dosing information, storage instructions, and manufacturer details for Major Pharmaceuticals located in Livonia, MI, and Rising Pharmaceuticals in Saddle Brook, NJ.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 03)

PREGABALIN CAPSULES 150 mg oral capsules by Major Pharmaceuticals. The label indicates unit dose packaging, 100 capsules, NDC 0904-7002-61, with pharmacist instructions to dispense with medication guide. Storage instructions and manufacturer information are included on the label.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 04)

PREGABALIN 100 mg capsules unit dose carton by Major Pharmaceuticals. The label features the proprietary name PREGABALIN in red and strength 100 mg in a gold box. It indicates the product is Rx only with 100 capsules supplied. Includes pharmacist instructions to dispense with medication guide and storage directions.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 05)

PREGABALIN Capsules 75 mg oral dosage form label by Major Pharmaceuticals. The label states unit dose packaging containing 100 capsules, prescription only, with instructions for pharmacist dispensing with a medication guide. It includes storage instructions and supplier information for Major Pharmaceuticals in Livonia, MI.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 06)

PREGABALIN CAPSULES 50 mg oral unit dose packaging label by Major Pharmaceuticals. The label indicates a total of 100 capsules and highlights that it is Rx only. It provides information about active ingredient content per capsule, storage instructions, and warnings. The label includes NDC 0904-6992-61 and distributor details for Major Pharmaceuticals.*

FDA Label Image

Carton Label (2420e2d7 C01a 4590 88c5 6fe5361747e9 07)

Label for Pregabalin Capsules 25 mg by Major Pharmaceuticals. The label includes the proprietary and generic name, strength of 25 mg per capsule, and states it is Rx only with a package of 30 capsules. It includes storage instructions, dosing note to see product insert, and distributor information for Major Pharmaceuticals in Livonia, MI.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of pregabalin, the active ingredient in PREGABALIN capsules. The diagram shows the molecular arrangement with functional groups including an amino group and carboxylic acid group.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for estimating creatinine clearance (CLCr) showing variables including age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor for female patients. This formula is typically used in pharmacokinetic calculations related to drug dosing.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules at 25 mg, 100 mg, and 200 mg three times a day compared to placebo. The graph shows trends of pain improvement over a range from less than 10% to 100% improvement in pain.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A Kaplan-Meier plot showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two curves are displayed, comparing pregabalin 100 mg three times a day versus placebo in terms of patient response over different pain improvement thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing percent improvement in patients from baseline pain over a range of percent improvements in pain. The graph compares four groups: Pregabalin 300 mg taken two times a day, Pregabalin 150 mg taken two times a day, Pregabalin 75 mg taken two times a day, and placebo. The y-axis is labeled as percent of patients improved, and the x-axis is labeled as percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph illustrating the percent of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends of patient improvement across different levels of pain improvement.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing the percent improvement in pain from baseline plotted against the percent of patients involved. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating different pain improvement rates over the range from 0 to 100 percent.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar chart showing responder rates (%) from two clinical studies (Study E1 and Study E3) comparing placebo and various doses of pregabalin (50 mg/day up to 600 mg/day) including once and thrice daily dosing. The x-axis lists treatment groups, and the y-axis shows responder rates from 0% to 60%. Statistically significant differences from placebo are indicated.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph showing seizure reduction (median % change from baseline) on the y-axis and dose (mg/day) on the x-axis. The graph compares four studies (E1 BID, E2 TID, E3 BID, E3 TID) with data points indicating significant p-values for dose effects up to 600 mg/day, highlighting seizure reduction response to increasing dose levels.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three Pregabalin daily doses (300 mg, 450 mg, 600 mg) and placebo. The graph depicts decreasing patient improvement as pain improvement percentage increases along the x-axis.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve graph depicting the estimated percentage of subjects without LTR over time in days, comparing Pregabalin and Placebo groups. The y-axis represents the estimated percentage, and the x-axis represents days, with Pregabalin showing a higher percentage of subjects without LTR than Placebo throughout the study period.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

Line graph comparing the percent of subjects improved from baseline to Week 12 for Pregabalin versus placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved, with Pregabalin consistently showing higher improvement across the scale compared to placebo.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 16 in a study of Pregabalin versus placebo. The vertical axis represents the percent of subjects improved, and the horizontal axis shows percent improvement from baseline to Week 16 BOCF. Two lines represent Pregabalin (solid) and placebo (dashed), showing greater improvement with Pregabalin over placebo throughout the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.